skip to main content

Call: 905 815 9283       Fax: 905 815 9492

Clinical Trials


Major cardiovascular and other patient important outcomes with personalized dialysate temperature, a cluster trial involving all 80 participating dialysis centres in Ontario assessing mortality and cardiovascular outcomes in dialysis patients.

  • This is a study that randomizes, or selects dialysis units randomly, to either have usual dialysate [the solution that helps remove toxins that develop from kidney failure] temperature, versus dialysate temperature that is cooler than the normal prescription.
  • Enrollment is by dialysis unit.

C-MAJOR (Canadian Medical Assessment of JINARC Outcomes Registry)

A Canadian registry study to follow patients with polycystic kidney disease who are on Tolvaptan therapy.

    • This study is a registry study that continues to monitor patients who are on Tolvaptan, a first in-class medication to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD). It evaluates symptoms, PKD related outcomes and adverse events.
    • Enrollment is offered to all those who are candidates for Tolvaptan and start on therapy.

DAPA Trial

A Study to Evaluate the Effect of Dapgliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease

Enrollment almost complete
    • This study looks at a diabetic medication, Dapaglifozin, a member of the SGLT2 inhibitor class of diabetic medications to prevent progression in kidney disease and cardiovascular outcomes.
    • Enrollment is still ongoing.

Olympus Study

An international trial to investigate a new molecule, Roxadustat, in the treatment of anemia in kidney disease.

Enrollment complete
    • This study looks at a new class of molecule, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHI) to keep active the pathway that stimulates an increase in hemoglobin (red blood cell production).
    • Enrollment for this study is complete.

Please speak to Dr. Pandeya and his team about these trials if you are interested in learning more.